HRP20201259T1 - Protutijela protiv ox40 i njihova upotreba - Google Patents
Protutijela protiv ox40 i njihova upotreba Download PDFInfo
- Publication number
- HRP20201259T1 HRP20201259T1 HRP20201259TT HRP20201259T HRP20201259T1 HR P20201259 T1 HRP20201259 T1 HR P20201259T1 HR P20201259T T HRP20201259T T HR P20201259TT HR P20201259 T HRP20201259 T HR P20201259T HR P20201259 T1 HRP20201259 T1 HR P20201259T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody against
- cdr
- Prior art date
Links
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 10
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (13)
1. Protutijelo protiv OX40, naznačeno time što sadrži (i) VH lanac koji ima tri CDR-a; i (ii) VL lanac koji ima tri CDR-a, gdje:
VH CDR br. 1 ima aminokiselinski slijed GFTFSRYGMS (SEQ ID NO:101), VH CDR br. 2 ima aminokiselinski slijed TINSNGGRTYYPDSVKG (SEQ ID NO:102), VH CDR br. 3 ima aminokiselinski slijed EGITTAYAMDY (SEQ ID NO:103), VL CDR br. 1 ima aminokiselinski slijed KASQSVDYDGDSYMH (SEQ ID NO:104), VL CDR br. 2 ima aminokiselinski slijed AASILES (SEQ ID NO:105), a VL CDR br. 3 ima aminokiselinski slijed QQSNEDPRT (SEQ ID NO:106).
2. Protutijelo protiv OX40 u skladu s patentnim zahtjevom 1, naznačeno time što je monoklonsko.
3. Protutijelo protiv OX40 u skladu s patentnim zahtjevom 1, naznačeno time što je humanizirano.
4. Protutijelo protiv OX40 u skladu s patentnim zahtjevom 3, naznačeno time što sadrži VH lanac koji ima aminokiselinski slijed:
EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYGMSWVRQAPGKGLELVATINSNG
GRTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGITTAYAMDY
WGQGTTVTVSS (SEQ ID NO:22);
i VL lanac koji ima aminokiselinski slijed:
DIVMTQSPDSLAVSLGERATINCKASQSVDYDGDSYMHWYQQKPGQPPKLLIYAA
SILESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPRTFGGGTKVEIK
(SEQ ID NO:32).
5. Protutijelo protiv OX40 u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačeno time što je IgG.
6. Protutijelo protiv OX40 u skladu s patentnim zahtjevom 5, naznačeno time što je IgG1.
7. Protutijelo protiv OX40 u skladu s patentnim zahtjevom 4, naznačeno time što sadrži teški lanac koji ima aminokiselinski slijed prem SEQ ID NO: 41 ili 42; i laki lanac koji ima aminokiselinski slijed prem SEQ ID NO: 51.
8. Jedna ili više nukleinskih kiselina, naznačene time što imaju nukleotidne sljedove koji kodiraju protutijelo protiv OX40 u skladu s bilo kojim od patentnih zahtjeva 1 do 7.
9. Jedan ili više vektora, naznačeni time što sadrže jednu ili više nukleinskih kiselina u skladu s patentnim zahtjevom 8.
10. Eukariotska stanica domaćin, naznačena time što je transformirana jednim ili više vektora u skladu s patentnim zahtjevom 9.
11. Eukariotska stanica domaćin, naznačena time što je genetički modificirana za eksprimiranje jedne ili više nukleinskih kiselina u skladu s patentnim zahtjevom 8.
12. Eukariotska stanica domaćin u skladu s patentnim zahtjevom 10 ili 11, naznačena time što je sisavačka stanica domaćin.
13. Postupak proizvodnje protutijela protiv OX40, naznačen time što se sastoji u: (a) uzgoju stanice domaćina u skladu s patentnim zahtjevom 10 ili patentnim zahtjevom 11; i (b) prikupljanju protutijela protiv OX40.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434761P | 2016-12-15 | 2016-12-15 | |
| PCT/US2017/066680 WO2018112346A1 (en) | 2016-12-15 | 2017-12-15 | Anti-ox40 antibodies and their uses |
| EP17826089.9A EP3504242B1 (en) | 2016-12-15 | 2017-12-15 | Anti-ox40 antibodies and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201259T1 true HRP20201259T1 (hr) | 2020-11-13 |
Family
ID=60937946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201259TT HRP20201259T1 (hr) | 2016-12-15 | 2020-08-11 | Protutijela protiv ox40 i njihova upotreba |
Country Status (36)
| Country | Link |
|---|---|
| US (7) | US10556962B2 (hr) |
| EP (2) | EP3725809A1 (hr) |
| JP (2) | JP6772385B2 (hr) |
| KR (2) | KR20210157471A (hr) |
| CN (1) | CN110573527A (hr) |
| AR (1) | AR110526A1 (hr) |
| AU (1) | AU2017377036B2 (hr) |
| BR (2) | BR122020025629B1 (hr) |
| CA (1) | CA3045940A1 (hr) |
| CL (1) | CL2019001646A1 (hr) |
| CO (1) | CO2019007288A2 (hr) |
| CR (1) | CR20190330A (hr) |
| CY (1) | CY1123274T1 (hr) |
| DK (1) | DK3504242T3 (hr) |
| DO (1) | DOP2019000165A (hr) |
| EC (1) | ECSP19050049A (hr) |
| ES (1) | ES2813057T3 (hr) |
| HR (1) | HRP20201259T1 (hr) |
| HU (1) | HUE050399T2 (hr) |
| IL (1) | IL267070A (hr) |
| LT (1) | LT3504242T (hr) |
| MA (1) | MA53184A (hr) |
| MX (1) | MX2019007121A (hr) |
| MY (1) | MY198059A (hr) |
| PE (1) | PE20191403A1 (hr) |
| PH (1) | PH12019501357A1 (hr) |
| PL (1) | PL3504242T3 (hr) |
| PT (1) | PT3504242T (hr) |
| RS (1) | RS60664B1 (hr) |
| RU (1) | RU2753493C2 (hr) |
| SG (1) | SG10201914126RA (hr) |
| SI (1) | SI3504242T1 (hr) |
| TW (1) | TWI734879B (hr) |
| UA (1) | UA125041C2 (hr) |
| UY (1) | UY37523A (hr) |
| WO (1) | WO2018112346A1 (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2813057T3 (es) * | 2016-12-15 | 2021-03-22 | Abbvie Biotherapeutics Inc | Anticuerpos anti-ox40 y sus usos |
| US20200181275A1 (en) * | 2017-06-09 | 2020-06-11 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy with icos agonist and ox40 agonist to treat cancer |
| WO2019028182A2 (en) * | 2017-08-01 | 2019-02-07 | Remd Biotherapeutics, Inc. | TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40) |
| CN110790837A (zh) * | 2018-08-02 | 2020-02-14 | 上海君实生物医药科技股份有限公司 | 抗btla抗体 |
| WO2020119789A1 (en) * | 2018-12-14 | 2020-06-18 | Wuxi Biologics (Shanghai) Co., Ltd. | Fully human antibodies against ox40, method for preparing the same, and use thereof |
| JP7346576B2 (ja) * | 2018-12-25 | 2023-09-19 | ハンクス バイオファーマシューティクス，インコーポレイテッド | 抗ｏｘ４０モノクローナル抗体とその応用 |
| CN110172090B (zh) * | 2019-06-03 | 2020-04-03 | 中山标佳生物科技有限公司 | Cd134单克隆抗体及其制备方法和癌症治疗中的应用 |
| WO2021098851A1 (en) * | 2019-11-20 | 2021-05-27 | Eucure (Beijing) Biopharma Co., Ltd | Anti-ctla4/ox40 bispecific antibodies and uses thereof |
| CA3162705A1 (en) | 2019-12-17 | 2021-06-24 | Amgen Inc. | Dual interleukin-2 /tnf receptor agonist for use in therapy |
| CN113045654A (zh) * | 2019-12-27 | 2021-06-29 | 南开大学 | 抗ox40抗体及其用途 |
| CN111303285B (zh) * | 2019-12-27 | 2023-06-02 | 百力司康生物医药(杭州)有限公司 | 靶向ox40的抗体及其制备方法和应用 |
| US20230139700A1 (en) * | 2020-03-23 | 2023-05-04 | Bio-Thera Solutions, Ltd. | Development and application of immune cell activator |
| US20230295324A1 (en) * | 2020-06-30 | 2023-09-21 | Harbour Biomed (Shanghai) Co., Ltd | Ox40-targeted antibody, and preparation method therefor and application thereof |
| CN111704671B (zh) * | 2020-08-19 | 2020-11-24 | 广东赛尔生物科技有限公司 | Ox40抗体及其在治疗癌症中的应用 |
| CN112442121A (zh) * | 2020-08-20 | 2021-03-05 | 山东兴瑞生物科技有限公司 | Ox40抗体、其编码基因、及抗体的制备方法和在增强人体免疫功能中的应用 |
| CN114106173A (zh) * | 2020-08-26 | 2022-03-01 | 上海泰槿生物技术有限公司 | 抗ox40抗体、其药物组合物及应用 |
| CN111763258B (zh) * | 2020-09-01 | 2020-12-29 | 北京百奥赛图基因生物技术有限公司 | 抗ox40抗体及其用途 |
| US20240018248A1 (en) | 2020-12-02 | 2024-01-18 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| CN115260312A (zh) * | 2021-04-30 | 2022-11-01 | 保诺科技（北京）有限公司 | 结合ox40的抗体或抗原结合片段 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| KR20050085971A (ko) | 1995-04-27 | 2005-08-29 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP2314625B1 (en) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| US7227002B1 (en) | 1997-04-14 | 2007-06-05 | Micromet Ag | Human antibodies that bind human 17-A1/EpCAM tumor antigen |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| ATE408011T1 (de) | 1998-02-24 | 2008-09-15 | Sisters Of Providence In Orego | Zusammensetzungen, die entweder ein ox-40- rezeptor-bindemittel oder eine für ein solches bindemittel kodierende nukleicsäuresequenz enthalten, und verfahren zur verbesserung der antigenspezifischen immunantwort |
| AU1728800A (en) | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| CA2489004C (en) | 2002-06-13 | 2013-01-08 | Crucell Holland B.V. | Agonistic binding molecules to the human ox40 receptor |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| US20080286286A1 (en) | 2006-01-13 | 2008-11-20 | Board Of Regents, The University Of Texas System | Methods to Treat Disease States by Influencing the Signaling of Ox-40-Receptors and High Throughput Screening Methods for Identifying Substances Therefor |
| EP2851374B1 (en) | 2007-12-14 | 2017-05-03 | Bristol-Myers Squibb Company | Binding molecules to the human OX40 receptor |
| DK2609118T3 (en) | 2010-08-23 | 2017-04-03 | Univ Texas | Anti-OX40 antibodies and methods for their use |
| CN103946238B (zh) * | 2011-08-23 | 2016-10-12 | 德克萨斯州立大学董事会 | 抗ox40抗体及使用其的方法 |
| US20140377253A1 (en) | 2013-03-15 | 2014-12-25 | Abbvie Biotherapeutics Inc. | Fc variants |
| PT2976361T (pt) * | 2013-03-18 | 2018-10-19 | Janssen Pharmaceuticals Inc | Anticorpos anti-cd134 (ox40) humanizados e utilizações dos mesmos |
| BR112016022345A2 (pt) | 2014-03-31 | 2017-10-10 | Genentech Inc | terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40 |
| TW201619200A (zh) | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| MX2017005751A (es) | 2014-11-03 | 2018-04-10 | Genentech Inc | Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40. |
| US10259882B2 (en) * | 2015-05-07 | 2019-04-16 | Agenus Inc. | Anti-OX40 antibodies |
| MX2017014699A (es) * | 2015-05-21 | 2018-04-11 | Alligator Bioscience Ab | Polipeptidos novedosos. |
| US20160347848A1 (en) * | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| MA43389A (fr) | 2015-12-02 | 2021-05-12 | Agenus Inc | Anticorps anti-ox40 et leurs procédés d'utilisation |
| ES2813057T3 (es) * | 2016-12-15 | 2021-03-22 | Abbvie Biotherapeutics Inc | Anticuerpos anti-ox40 y sus usos |
-
2017
- 2017-12-15 ES ES17826089T patent/ES2813057T3/es active Active
- 2017-12-15 PL PL17826089T patent/PL3504242T3/pl unknown
- 2017-12-15 PE PE2019001249A patent/PE20191403A1/es unknown
- 2017-12-15 MY MYPI2019003403A patent/MY198059A/en unknown
- 2017-12-15 CR CR20190330A patent/CR20190330A/es unknown
- 2017-12-15 HU HUE17826089A patent/HUE050399T2/hu unknown
- 2017-12-15 BR BR122020025629-0A patent/BR122020025629B1/pt active IP Right Grant
- 2017-12-15 EP EP20173858.0A patent/EP3725809A1/en not_active Withdrawn
- 2017-12-15 EP EP17826089.9A patent/EP3504242B1/en active Active
- 2017-12-15 MX MX2019007121A patent/MX2019007121A/es unknown
- 2017-12-15 KR KR1020217041290A patent/KR20210157471A/ko active Application Filing
- 2017-12-15 AU AU2017377036A patent/AU2017377036B2/en not_active Ceased
- 2017-12-15 RU RU2019121895A patent/RU2753493C2/ru active
- 2017-12-15 TW TW106144235A patent/TWI734879B/zh not_active IP Right Cessation
- 2017-12-15 UA UAA201907981A patent/UA125041C2/uk unknown
- 2017-12-15 UY UY0001037523A patent/UY37523A/es not_active Application Discontinuation
- 2017-12-15 US US15/843,281 patent/US10556962B2/en active Active
- 2017-12-15 PT PT178260899T patent/PT3504242T/pt unknown
- 2017-12-15 LT LTEP17826089.9T patent/LT3504242T/lt unknown
- 2017-12-15 KR KR1020197020437A patent/KR102341926B1/ko active IP Right Grant
- 2017-12-15 SG SG10201914126RA patent/SG10201914126RA/en unknown
- 2017-12-15 CA CA3045940A patent/CA3045940A1/en not_active Abandoned
- 2017-12-15 BR BR112019012328-8A patent/BR112019012328A2/pt not_active Application Discontinuation
- 2017-12-15 JP JP2019531934A patent/JP6772385B2/ja not_active Expired - Fee Related
- 2017-12-15 MA MA053184A patent/MA53184A/fr unknown
- 2017-12-15 CN CN201780086610.XA patent/CN110573527A/zh active Pending
- 2017-12-15 DK DK17826089.9T patent/DK3504242T3/da active
- 2017-12-15 SI SI201730380T patent/SI3504242T1/sl unknown
- 2017-12-15 WO PCT/US2017/066680 patent/WO2018112346A1/en unknown
- 2017-12-15 AR ARP170103527A patent/AR110526A1/es unknown
- 2017-12-15 RS RS20200923A patent/RS60664B1/sr unknown
-
2018
- 2018-02-28 US US15/908,221 patent/US10040864B2/en active Active
- 2018-08-06 US US16/056,042 patent/US20180346593A1/en not_active Abandoned
-
2019
- 2019-06-03 IL IL267070A patent/IL267070A/en unknown
- 2019-06-13 DO DO2019000165A patent/DOP2019000165A/es unknown
- 2019-06-14 CL CL2019001646A patent/CL2019001646A1/es unknown
- 2019-06-14 PH PH12019501357A patent/PH12019501357A1/en unknown
- 2019-07-08 CO CONC2019/0007288A patent/CO2019007288A2/es unknown
- 2019-07-12 EC ECSENADI201950049A patent/ECSP19050049A/es unknown
- 2019-10-24 US US16/663,131 patent/US10604584B2/en active Active
-
2020
- 2020-02-20 US US16/796,622 patent/US20200181282A1/en not_active Abandoned
- 2020-08-11 HR HRP20201259TT patent/HRP20201259T1/hr unknown
- 2020-08-21 CY CY20201100785T patent/CY1123274T1/el unknown
- 2020-09-29 JP JP2020162944A patent/JP2021019603A/ja active Pending
- 2020-10-02 US US17/062,474 patent/US20210017289A1/en not_active Abandoned
-
2021
- 2021-12-23 US US17/560,664 patent/US20220112304A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201259T1 (hr) | Protutijela protiv ox40 i njihova upotreba | |
| HRP20201993T1 (hr) | Protutijela protiv pd-1 | |
| JP2020504101A5 (hr) | ||
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| JP2018520657A5 (hr) | ||
| HRP20211794T1 (hr) | Humana antitijela za pd-1 | |
| HRP20191704T1 (hr) | Multispecifična protutijela | |
| HRP20200382T1 (hr) | Humanizirana ili kimerna protutijela cd3 | |
| HRP20191470T1 (hr) | Heterodimerni proteini | |
| HRP20210364T1 (hr) | Anti-gitr antitijela i postupci za njihovu primjenu | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| HRP20220787T1 (hr) | Protutijela protiv garp-tgf-beta | |
| HRP20192280T1 (hr) | Anti-ceacam6 protutijela i njihova uporaba | |
| EP4286415A3 (en) | Humanized antigen-binding domains against cd19 and methods of use | |
| HRP20200189T1 (hr) | Anti-tigit antitijela, anti-pvrig antitijela i njihove kombinacije | |
| HRP20131167T1 (hr) | Antitijela za humani receptor programirane smrti pd-1 | |
| JP2017114866A5 (hr) | ||
| HRP20231579T1 (hr) | Anti-ctla-4 antitijela i postupci njihove upotrebe | |
| HRP20230060T1 (hr) | Antitijela protiv ox40 i njihova primjena | |
| JP2018527919A5 (hr) | ||
| JP2019500862A5 (hr) | ||
| HRP20211820T1 (hr) | Anti-tim-3 protutijela i pripravci | |
| HRP20231456T1 (hr) | Protutijela protiv c5 i njihova upotreba | |
| HRP20150623T1 (hr) | Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen | |
| HRP20151213T1 (hr) | Anti-c5a protutijela i postupci za uporabu protutijela |